North America Topical Drug Delivery Market Overview by Global Product Type, Distribution Channel, End User, Geography, Top Key Players MedPharm, Janssen Pharmaceuticals, Inc.

North America Topical Drug Delivery Market, By Product Type {Topical Drug Delivery Formulations (Solid, Liquid, Semi-Solid), Transdermal Drug Delivery Devices (Patches, Gels)}, End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others), Distribution Channel (Direct Tenders, Retail), Country (U.S, Canada, Mexico) – Trends and Forecast to 2024

Get Free Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=north-america-topical-drug-delivery-market

Major Market Competitors:

Some of the major players operating in this market are MedPharm, Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services Inc A J&J Company), Crescita Therapeutics, Galderma S.A., Biofarmitalia s.r.l, Pharmatek Laboratories, Inc., Stiefel Laboratories, Inc., Tapemark, Acrux Limited, Nitto Denko Corporation, Valeant Pharmaceuticals International, Inc., Skinvisible Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co., Inc., Pocono Coated Products LLC, TheraSolve NV., Samyang Biopharmaceuticals Corporation, Lohmann Therapie-Systeme AG, Prosollus Pharmaceuticals, Easton Pharmaceuticals Inc., Novosis AG, Antares Pharma, Inc., Endo Pharmaceuticals Inc., Transdermal Technologies, Inc., Sheffield Pharmaceuticals, Inc., Solvay, and 3M Drug Delivery Systems.

Market Analysis:

North America Topical Drug Delivery Market is expected to reach USD 89.3 billion by 2024 from USD 48.0 billion in 2016, growing at a CAGR of 8.0% in the forecast period 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.

Inquiry before Buying about this Market Visit @ http://databridgemarketresearch.com/inquire-before-buying/?dbmr=north-america-topical-drug-delivery-market

Scope of the Report:

The North America Topical Drug Delivery Market is segmented on the basis of product type, distribution channel, end user, and geography.

On the basis of product typethe market is segmented into transdermal drug delivery devices and topical drug delivery formulations. Topical drug delivery formulations are further segmented based on form into solid, semi-solid, and liquid. The semi solid segment is further classified into ointments, creams, lotions, gels, and pastes. The solid drugs segment is further segmented into powders and suppositors. The liquid drugs segment is further classified into solutions and suspensions.

The transdermal drug delivery devices market segment is further segmented into patches and gels. In 2016, on the basis of product type topical drug delivery formulations segment dominated the market by 72.6% share, however transdermal drug delivery devices market is expected to grow at the highest CAGR of 14.1% in the forecast period 2017 to 2024.

On the basis of end users, the market is segmented into hospitals, home healthcare, clinics, diagnostic centers, and others.

Company Share Analysis:

The North America topical drug delivery market is highly fragmented with various companies operating in local regions. The major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.

Browse Full Report Visit @ http://databridgemarketresearch.com/reports/north-america-topical-drug-delivery-market/

Table of Contents:

1. INTRODUCTION
1.1. OVERVIEW OF THE NORTHA AMERICA TOPICAL DRUG DELIVERY MARKET
1.2. MARKET SEGMENTATION & COVERAGE
1.2.1. CURRENCY AND PRICING
1.2.2. LIMITATION
1.2.3. STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE NORTH AMERICA TOPICAL DRUG DELIVERY MARKET SIZE
2.2.1. MARKET CRACKDOWN APPROACH
2.2.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
2.2.3. DATA TRIANGULATION
2.2.4. KEY DATA POINTS FROM PRIMARY SOURCES
2.2.5. PRODUCT PIPELINE ANALYSIS
2.2.6. PORTER’S FIVE FORCES MATRIX
2.4. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.5. ASSUMPTIONS
3. MARKET LANDSCAPE SUMMARY
4. PREMIUM INSIGHTS
4.1. OVERVIEW
4.2. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: KEY PRIMARY INSIGHTS
4.3. MARKET OVERVIEW
4.3.1. DRIVERS
4.3.1.1. RISING PREVALENCE OF CHRONIC DISEASE SUCH AS DIABETES
4.3.1.2. GROWTH IN TRANSDERMAL TECHNOLOGY
4.3.1.3. INNOVATION AND DEVELOPMENT OF NEW DRUG TYPES
4.3.1.4. BETTER HEALTHCARE SPENDING IN SOUTH ASIA AND AFRICA
4.3.2. RESTRAINTS
4.3.3. OPPURTUNITIES
4.3.4. THREATS
4.4. KEY MARKET TRENDS AND UPCOMING TECHNOLOGIES
5. EXECUTIVE SUMMARY
6. TOPICAL DRUG DELIVERY MARKET, BY PRODUCT TYPE
6.1. OVERVIEW
6.2. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
6.2.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
6.2.1.1. TRANSDERMAL PATCHES
6.2.1.2. TRANSDERMAL GELS
6.2.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
6.2.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.1.1. SOLUTIONS
6.2.2.1.2. SUSPENSIONS
6.2.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.2.1. GELS
6.2.2.2.2. CREAMS
6.2.2.2.3. OINTMENTS
6.2.2.2.4. PASTES
6.2.2.2.5. LOTIONS
6.2.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
6.2.2.3.1. SUPPOSITORIES
6.2.2.3.2. POWDERS
7. TOPICAL DRUG DELIVERY MARKET, BY END-USER
7.1. OVERVIEW
7.2. HOSPITALS
7.3. HOME HEALTHCARE
7.4. CLINICS
7.5. DIAGNOSTIC CENTERS
7.6. OTHERS
8. TOPICAL DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. HOSPITAL PHARMACIES
8.3. PHARMACY STORES
8.4. DIRECT TENDERS
8.5. ONLINE PHARMACY
9. TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY
9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
9.1.1. NORTH AMERICA
9.1.1.1. U.S.
9.1.1.2. CANADA
9.1.1.3. MEXICO
9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
10. TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LANDSCAPE
10.1. NORTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.2. U.S. TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.3. EUROPE TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.4. APAC TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.5. SOUTH AMERICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.6. MIDDLE EAST AND AFRICA TOPICAL DRUG DELIVERY MARKET: COMPANY SHARE ANALYSIS
10.7. MERGERS & ACQUISITIONS
10.8. NEW PRODUCT DEVELOPMENT & APPROVALS
10.10. EXPANSIONS
10.10. REGULATORY CHANGES
10.11. PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
11. TOPICAL DRUG DELIVERY MARKET, COMPANY PROFILES
11.1. JANSSEN PHARMACEUTICALS, INC. (A J&J COMPANY)
11.1.1. COMPANY OVERVIEW
11.1.2. SWOT ANALYSIS
11.1.3. REVENUE ANALYSIS
11.1.4. PRODUCT PORTFOLIO
11.1.5. RECENT DEVELOPEMENTS
11.1.5. DATA BRIDGE ANALYSIS
11.2. CRESCITA THERAPEUTICS
11.2.1. COMPANY OVERVIEW
11.2.2. SWOT ANALYSIS
11.2.3. REVENUE ANALYSIS
11.2.4. PRODUCT PORTFOLIO
11.2.5. RECENT DEVELOPEMENTS
11.2.5. DATA BRIDGE ANALYSIS
11.3. GALDERMA S.A.
11.3.1. COMPANY OVERVIEW
11.3.2. SWOT ANALYSIS
11.3.3. REVENUE ANALYSIS
11.3.4. PRODUCT PORTFOLIO
11.3.5. RECENT DEVELOPEMENTS
11.3.6. DATA BRIDGE ANALYSIS
11.4. BIOFARMITALIA S.R.L
11.4.1. COMPANY OVERVIEW
11.4.2. SWOT ANALYSIS
11.4.3. REVENUE ANALYSIS
11.4.4. PRODUCT PORTFOLIO
11.4.5. RECENT DEVELOPEMENTS
11.4.5. DATA BRIDGE ANALYSIS
11.5. PHARMATEK LABORATORIES, INC.
11.5.1. COMPANY OVERVIEW
11.5.2. SWOT ANALYSIS
11.5.3. REVENUE ANALYSIS
11.5.4. PRODUCT PORTFOLIO
11.5.5. RECENT DEVELOPEMENTS
11.5.5. DATA BRIDGE ANALYSIS
11.6. STIEFEL LABORATORIES, INC.
11.6.1. COMPANY OVERVIEW
11.6.2. SWOT ANALYSIS
11.6.3. REVENUE ANALYSIS
11.6.4. PRODUCT PORTFOLIO
11.6.5. RECENT DEVELOPEMENTS
11.6.5. DATA BRIDGE ANALYSIS
11.7. TAPEMARK
11.7.1. COMPANY OVERVIEW
11.7.2. SWOT ANALYSIS
11.7.3. REVENUE ANALYSIS
11.7.4. PRODUCT PORTFOLIO
11.7.5. RECENT DEVELOPEMENTS
11.7.6. DATA BRIDGE ANALYSIS
11.8. NITTO DENKO CORPORATION
11.8.1. COMPANY OVERVIEW
11.8.2. SWOT ANALYSIS
11.8.3. REVENUE ANALYSIS
11.8.4. PRODUCT PORTFOLIO
11.8.5. RECENT DEVELOPEMENTS
11.8.6. DATA BRIDGE ANALYSIS
11.9. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
11.9.1. COMPANY OVERVIEW
11.9.2. SWOT ANALYSIS
11.9.3. REVENUE ANALYSIS
11.9.4. PRODUCT PORTFOLIO
11.9.5. RECENT DEVELOPEMENTS
11.9.6. DATA BRIDGE ANALYSIS
11.9. MYLAN PHARMACEUTICALS INC.
11.9.1. COMPANY OVERVIEW
11.9.2. SWOT ANALYSIS
11.9.3. REVENUE ANALYSIS
11.9.4. PRODUCT PORTFOLIO
11.9.5. RECENT DEVELOPEMENTS
11.9.6. DATA BRIDGE ANALYSIS
11.9. HISAMITSU PHARMACEUTICAL CO., INC.
11.9.1. COMPANY OVERVIEW
11.9.2. SWOT ANALYSIS
11.9.3. REVENUE ANALYSIS
11.9.4. PRODUCT PORTFOLIO
11.9.5. RECENT DEVELOPEMENTS
11.9.5. DATA BRIDGE ANALYSIS
11.10. THERASOLVE NV.
11.10.1. COMPANY OVERVIEW
11.10.2. SWOT ANALYSIS
11.10.3. REVENUE ANALYSIS
11.10.4. PRODUCT PORTFOLIO
11.10.5. RECENT DEVELOPEMENTS
11.10.6. DATA BRIDGE ANALYSIS
11.11. SAMYANG BIOPHARMACEUTICALS CORPORATION
11.11.1. COMPANY OVERVIEW
11.11.2. SWOT ANALYSIS
11.11.3. REVENUE ANALYSIS
11.11.4. PRODUCT PORTFOLIO
11.11.5. RECENT DEVELOPEMENTS
11.11.6. DATA BRIDGE ANALYSIS
11.12. LOHMANN THERAPIE-SYSTEME AG
11.12.1. COMPANY OVERVIEW
11.12.2. SWOT ANALYSIS
11.12.3. REVENUE ANALYSIS
11.12.4. PRODUCT PORTFOLIO
11.12.5. RECENT DEVELOPEMENTS
11.12.6. DATA BRIDGE ANALYSIS
11.13. PROSOLLUS PHARMACEUTICALS
11.13.1. COMPANY OVERVIEW
11.13.2. SWOT ANALYSIS
11.13.3. REVENUE ANALYSIS
11.13.4. PRODUCT PORTFOLIO
11.13.5. RECENT DEVELOPEMENTS
11.13.6. DATA BRIDGE ANALYSIS
11.14. EASTON PHARMACEUTICALS INC.
11.14.1. COMPANY OVERVIEW
11.14.2. SWOT ANALYSIS
11.14.3. REVENUE ANALYSIS
11.14.4. PRODUCT PORTFOLIO
11.14.5. RECENT DEVELOPEMENTS
11.14.6. DATA BRIDGE ANALYSIS
11.15. ANTARES PHARMA, INC.
11.15.1. COMPANY OVERVIEW
11.15.2. SWOT ANALYSIS
11.15.3. REVENUE ANALYSIS
11.15.4. PRODUCT PORTFOLIO
11.15.5. RECENT DEVELOPEMENTS
11.15.6. DATA BRIDGE ANALYSIS
11.16. ENDO PHARMACEUTICALS INC.
11.16.1. COMPANY OVERVIEW
11.16.2. SWOT ANALYSIS
11.16.3. REVENUE ANALYSIS
11.16.4. PRODUCT PORTFOLIO
11.16.5. RECENT DEVELOPEMENTS
11.16.6. DATA BRIDGE ANALYSIS
11.17. TRANSDERMAL TECHNOLOGIES, INC.
11.17.1. COMPANY OVERVIEW
11.17.2. SWOT ANALYSIS
11.17.3. REVENUE ANALYSIS
11.17.4. PRODUCT PORTFOLIO
11.17.5. RECENT DEVELOPEMENTS
11.17.6. DATA BRIDGE ANALYSIS
11.18. SHEFFIELD PHARMACEUTICALS, INC.
11.18.1. COMPANY OVERVIEW
11.18.2. SWOT ANALYSIS
11.18.3. REVENUE ANALYSIS
11.18.4. PRODUCT PORTFOLIO
11.18.5. RECENT DEVELOPEMENTS
11.18.6. DATA BRIDGE ANALYSIS
11.19. SOLVAY
11.19.1. COMPANY OVERVIEW
11.19.2. SWOT ANALYSIS
11.19.3. REVENUE ANALYSIS
11.19.4. PRODUCT PORTFOLIO
11.19.5. RECENT DEVELOPEMENTS
11.19.6. DATA BRIDGE ANALYSIS
11.20. 3M DRUG DELIVERY SYSTEMS
11.20.1. COMPANY OVERVIEW
11.20.2. SWOT ANALYSIS
11.20.3. REVENUE ANALYSIS
11.20.4. PRODUCT PORTFOLIO
11.20.5. RECENT DEVELOPEMENTS
11.20.6. DATA BRIDGE ANALYSIS

Related Report

Global Topical Drug Delivery Market – Trends and Forecast to 2024

Global Topical Drug Delivery Market, By Product Type {Topical (Solid, Liquid, Semi-Solid), Transdermal (Patches, Gels)}; End-User (Hospitals, Clinics, Home Healthcare, Diagnostic Centers, Others); Distribution Channel (Direct Tenders, Retail); Geography (North America, Europe, Asia-Pacific, Latin America, Rest of the World) – Trends and Forecast to 2024

Report Access: http://databridgemarketresearch.com/reports/global-topical-drug-delivery-market/

About Data Bridge Market Research:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get 10% Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.

Contact:
Vishal Dixit
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

This release was published on openPR.